Haplotype-based analysis of common variation in the growth hormone receptor gene and prostate cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 1, 2007, Pages 169-173

  McKay, James D ^a,b   Kaaks, Rudolf ^a,d   Johansson, Mattias ^c   Biessy, Carine ^a   Wiklund, Fredik ^e   Bälter, Katarina ^e   Adami, Hans Olov ^e   Boillot, Catherine ^a   Gioia Patricola, Lydie ^a   Canzian, Federico ^a,d   Stattin, Pär ^c   Grönberg, Henrik ^e  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RECEPTOR;

3' UNTRANSLATED REGION; AGED; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; GENETIC IMMUNIZATION; HAPLOTYPE; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; SWEDEN;

AGED; CASE-CONTROL STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 33846625607     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0320     Document Type: Article

References (34)

1. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37.
2. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-89.
3. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
4. Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001;85:991-6.
5. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106.
6. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004;22:3104-12.
7. Hong Y, Pedersen NL, Brismar K, Hall K, de Faire U. Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 1996;81:1791-7.
8. Harrela M, Koistinen H, Kaprio J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996;98:2612-5.
9. Verhaeghe J, Loos R, Vlietinck R, Herck EV, van Bree R, Schutter AM. C-peptide, insulin-like growth factors I and II, and insulin-like growth factor binding protein-1 in cord serum of twins: genetic versus environmental regulation. Am J Obstet Gynecol 1996;175:1180-8.
10. Cheng I, Stram DO, Penney KL, et al. Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 2006;98:123-34.
11. Johansson M, McKay JD, Stattin P, et al. Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer. Int J Cancer 2007;120:539-42.
12. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994;15:369-90.
13. Zhou Y, Xu BC, Maheshwari HG, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci U S A 1997;94:13215-20.
14. Wang Z, Prins GS, Coschigano KT, et al. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology 2005;146:5188-96.
15. Weiss-Messer E, Merom O, Adi A, et al. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol Cell Endocrinol 2004;220:109-23.
16. Hsieh CL, Oakley-Girvan I, Balise RR, et al. A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity. Am J Hum Genet 2001;69:148-58.
17. Wiklund F, Gillanders EM, Albertus JA, et al. Genome-wide scan of Swedish families with hereditary prostate cancer: suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate 2003;57:290-7.
18. Goddard KA, Witte JS, Suarez BK, Catalona WJ, Olson JM. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet 2001;68:1197-206.
19. Camp NJ, Farnham JM, Cannon Albright LA. Genomic search for prostate cancer predisposition loci in Utah pedigrees. Prostate 2005;65:365-75.
20. Xu J, Dimitrov L, Chang BL, et al. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005;77:219-29.
21. Sun J, Wiklund F, Zheng SL, et al. Sequence variants in Toll-like receptor gene cluster (TLR6-1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005;97:525-32.
22. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S. Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 2000;275:18664-9.
23. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
24. Stram DO. Available from: http://www-rcf.usc.edu/~stram/tagSNPs.html. 2005.
25. Canzian F, McKay JD, Cleveland RJ, et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 2006;94:299-307.
26. Breslow NE, Day NE. Statistical methods in cancer research. Volume I-the analysis of case-control studies. IARC Sci Publ 1980;5-338.
27. Allison P. Logistic regression using SAS: theory and application. 1999;302.
28. Berryman DE, List EO, Kohn DT, Coschigano KT, Seeley RJ, Kopchick JJ. Effect of growth hormone on susceptibility to diet-induced obesity. Endocrinology 2006;147:2801-8.
29. Haiman CA, Stram DO, Pike MC, et al. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 2003;12:2679-92.
30. Freedman ML, Penney KL, Stram DO, et al. A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk. Cancer Res 2005;65:7516-22.
31. Olsson B, Bohlooly-Y M, Fitzgerald SM, et al. Bovine growth hormone transgenic mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet. Endocrinology 2005;146:920-30.
32. Valerio G, Bond HM, Badolato R, et al. Expression of growth hormone receptor by peripheral blood lymphocytes in children: evaluation in clinical conditions of impaired growth. Clin Endocrinol (Oxf) 1997;47:329-35.
33. Baessler A, Hasinoff MJ, Fischer M, et al. Genetic linkage and association of the growth hormone secretagogue receptor (ghrelin receptor) gene in human obesity. Diabetes 2005;54:259-67.
34. Ukkola O, Ravussin E, Jacobson P, et al. Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. J Clin Endocrinol Metab 2001;86:3996-9.